Allosteric HIV-1 integrase inhibitors promote aberrant protein multimerization by directly mediating inter-subunit interactions: Structural and thermodynamic modeling studies

Protein Science

Volumn 25, Issue 11, 2016, Pages 1911-1917

  Deng, Nanjie ^a   Hoyte, Ashley ^b   Mansour, Yara E ^b,c   Mohamed, Mosaad S ^c   Fuchs, James R ^b   Engelman, Alan N ^d   Kvaratskhelia, Mamuka ^b   Levy, Ronald ^a  

^a Temple University   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c Helwan   (Egypt)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

allosteric HIV 1 integrase inhibitor; HIV 1 integrase; protein ligand binding; protein protein docking

Indexed keywords

ALLOSTERIC HUMAN IMMUNODEFICIENCY VIRUS 1 INTEGRASE INHIBITOR 2; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BI 224436; INTEGRASE INHIBITOR; KF 116; KF 134; LENS EPITHELIUM DERIVED GROWTH FACTOR; PROTEIN P75; UNCLASSIFIED DRUG; INTEGRASE; P31 INTEGRASE PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEUTERIUM HYDROGEN EXCHANGE; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; HYDROPHOBICITY; MOLECULAR DOCKING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MULTIMERIZATION; THERMODYNAMICS; ALLOSTERISM; CHEMICAL MODEL; CHEMISTRY; ENZYMOLOGY; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; MODELS, CHEMICAL; MODELS, MOLECULAR; PROTEIN MULTIMERIZATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84992371644     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2997     Document Type: Article

References (29)

1. Jurado KA, Wang H, Slaughter A, Feng L, Kessl JJ, Koh Y, Wang W, Ballandras-Colas A, Patel PA, Fuchs JR, Kvaratskhelia M, Engelman A (2013) Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proc Natl Acad Sci USA 110:8690–8695.
2. Engelman A, Cherepanov P (2014) Retroviral integrase structure and DNA recombination mechanism. Microbiol Spect 2:1–22.
3. Masuda T (2011) Non-enzymatic functions of retroviral integrase: the next target for novel anti-HIV drug development. Front Microbiol 2:210.
4. Christ F, Voet A, Marchand A, Nicolet S, Desimmie BA, Marchand D, Bardiot D, Van der Veken NJ, Van Remoortel B, Strelkov SV, De Maeyer M, Chaltin P, Debyser Z (2010) Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6:442–448.
5. Engelman A, Kessl JJ, Kvaratskhelia M (2013) Allosteric inhibition of HIV-1 integrase activity. Curr Opin Chem Biol 17:339–345.
6. Demeulemeester J, Chaltin P, Marchand A, De Maeyer M, Debyser Z, Christ F (2014) LEDGINs, non-catalytic site inhibitors of HIV-1 integrase: a patent review (2006 – 2014). Expert Opin Ther Pat 24:609–632.
7. Feng L, Larue RC, Slaughter A, Kessl JJ, Kvaratskhelia M, HIV-1 integrase multimerization as a therapeutic target. In: Torbett BE, Goodsell DS, Richman DD, Eds. (2015) The future of HIV-1 therapeutics. Vol. 389. Switzerland: Springer International Publishing. pp 93–119. Available from http://link.springer.com/10.1007/82_2015_439.
8. Craigie R, Bushman FD (2012) HIV DNA integration. Cold Spring Harb Perspect Med 2:a006890.
9. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SFJ, Engelman A, Fuchs JR, Kvaratskhelia M (2012) Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 287:16801–16811.
10. Desimmie B, Schrijvers R, Demeulemeester J, Borrenberghs D, Weydert C, Thys W, Vets S, Van Remoortel B, Hofkens J, De Rijck J, Hendrix J, Bannert N, Gijsbers R, Christ F, Debyser Z (2013) LEDGINs inhibit late stage HIV-1 replication by modulating integrase multimerization in the virions. Retrovirology 10:57.
11. Balakrishnan M, Yant SR, Tsai L, O'Sullivan C, Bam RA, Tsai A, Niedziela-Majka A, Stray KM, Sakowicz R, Cihlar T (2013) Non-catalytic site HIV-1 integrase inhibitors disrupt core maturation and induce a reverse transcription block in target cells. PLoS One 8:e74163.
12. Gupta K, Brady T, Dyer BM, Malani N, Hwang Y, Male F, Nolte RT, Wang L, Velthuisen E, Jeffrey J, Van Duyne GD, Bushman FD (2014) Allosteric inhibition of human immunodeficiency virus integrase: late block during viral replication and abnormal multimerization involving specific protein domains. J Biol Chem 289:20477–20488.
13. Fontana J, Jurado KA, Cheng N, Ly NL, Fuchs JR, Gorelick RJ, Engelman AN, Steven AC (2015) Distribution and redistribution of HIV-1 nucleocapsid protein in immature, mature, and integrase-inhibited virions: a role for integrase in maturation. J Virol 89:9765–9780.
14. Slaughter A, Jurado KA, Deng N, Feng L, Kessl JJ, Shkriabai N, Larue RC, Fadel HJ, Patel PA, Jena N, Fuchs JR, Poeschla E, Levy RM, Engelman A, Kvaratskhelia M (2014) The mechanism of H171T resistance reveals the importance of Ndelta-protonated His171 for the binding of allosteric inhibitor BI-D to HIV-1 integrase. Retrovirology 11:100.
15. Feng L, Sharma A, Slaughter A, Jena N, Koh Y, Shkriabai N, Larue RC, Patel PA, Mitsuya H, Kessl JJ, Engelman A, Fuchs JR, Kvaratskhelia M (2013) The A128T resistance mutation reveals aberrant protein multimerization as the primary mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 288:15813–15820.
16. Fenwick C, Amad M, Bailey MD, Bethell R, Bos M, Bonneau P, Cordingley M, Coulombe R, Duan J, Edwards P, Fader LD, Faucher A-M, Garneau M, Jakalian A, Kawai S, Lamorte L, LaPlante S, Luo L, Mason S, Poupart M-A, Rioux N, Schroeder P, Simoneau B, Tremblay S, Tsantrizos Y, Witvrouw M, Yoakim C (2014) Preclinical profile of BI 224436, a novel HIV-1 non-catalytic-site integrase inhibitor. Antimicrob Agents Chemother 58:3233–3244.
17. Shkriabai N, Dharmarajan V, Slaughter A, Kessl JJ, Larue RC, Feng L, Fuchs JR, Griffin PR, Kvaratskhelia M (2014) A critical role of the C-terminal segment for allosteric inhibitor-induced aberrant multimerization of HIV-1 integrase. J Biol Chem 289:26430–26440.
18. Dominguez C, Boelens R, Bonvin AMJJ (2003) HADDOCK: a protein−protein docking approach based on biochemical or biophysical information. J Am Chem Soc 125:1731–1737.
19. van Zundert GCP, Rodrigues JPGLM, Trellet M, Schmitz C, Kastritis PL, Karaca E, Melquiond ASJ, van Dijk M, de Vries SJ, Bonvin AMJJ (2016) The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol 428:720–725.
20. Sharma A, Slaughter A, Jena N, Feng L, Kessl JJ, Fadel HJ, Malani N, Male F, Wu L, Poeschla E, Bushman FD, Fuchs JR, Kvaratskhelia M (2014) A new class of multimerization selective inhibitors of HIV-1 integrase. PLoS Pathog 10:e1004171.
21. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC, Mainz DT (2006) Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein−ligand complexes. J Med Chem 49:6177–6196.
22. Young T, Abel R, Kim B, Berne BJ, Friesner RA (2007) Motifs for molecular recognition exploiting hydrophobic enclosure in protein-ligand binding. Proc Natl Acad Sci USA 104:808–813.
23. Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R (2009) Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN Dimer-LEDGF) complex. J Biol Chem 284:33580–33599.
24. Feng L, Dharmarajan V, Serrao E, Hoyte A, Larue RC, Slaughter A, Sharma A, Plumb MR, Kessl JJ, Fuchs JR, Bushman FD, Engelman AN, Griffin PR, Kvaratskhelia M (2016) The competitive interplay between allosteric HIV-1 integrase inhibitor BI/D and LEDGF/p75 during the early stage of HIV-1 replication adversely affects inhibitor potency. ACS Chem Biol 11:1313–1321.
25. Bogan AA, Thorn KS (1998) Anatomy of hot spots in protein interfaces. J Mol Biol 280:1–9.
26. Moreira IS, Fernandes PA, Ramos MJ (2007) Hot spots-a review of the protein-protein interface determinant amino-acid residues. Proteins 68:803–812.
27. Deng N-J, Cieplak P (2009) Insights into affinity and specificity in the complexes of α-lytic protease and its inhibitor proteins: binding free energy from molecular dynamics simulation. Phys Chem Chem Phys 11:4968.
28. Fader LD, Malenfant E, Parisien M, Carson R, Bilodeau F, Landry S, Pesant M, Brochu C, Morin S, Chabot C, Halmos T, Bousquet Y, Bailey MD, Kawai SH, Coulombe R, LaPlanate S, Jakalian A, Bhardwaj PK, Wernic D, Schroeder P, Amad M, Edwards P, Garneau M, Duan J, Cordingley M, Bethell R, Mason SW, Bos M, Bonneau P, Poupart M-A, Faucher A-M, Simoneau B, Fenwick C, Yoakim C, Tsantrizos Y (2014) Discovery of BI 224436, a noncatalytic site integrase inhibitor (NCINI) of HIV-1. ACS Med Chem Lett 5:422–427.
29. Chen JC-H, Krucinski J, Miercke LJW, Finer-Moore JS, Tang AH, Leavitt AD, Stroud RM (2000) Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 97:8233–8238.